Great Lakes Retirement Inc. grew its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,562 shares of the company’s stock after buying an additional 820 shares during the period. Great Lakes Retirement Inc.’s holdings in Merck & Co., Inc. were worth $2,335,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth $39,000. Abich Financial Wealth Management LLC raised its stake in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after purchasing an additional 179 shares during the period. Quarry LP acquired a new position in Merck & Co., Inc. in the 2nd quarter valued at about $42,000. Strategic Financial Concepts LLC grew its stake in shares of Merck & Co., Inc. by 1,475.6% in the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after buying an additional 32,832 shares during the period. Finally, Ruedi Wealth Management Inc. increased its holdings in shares of Merck & Co., Inc. by 27.7% during the 2nd quarter. Ruedi Wealth Management Inc. now owns 397 shares of the company’s stock worth $49,000 after buying an additional 86 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.
Merck & Co., Inc. Trading Down 0.2 %
NYSE MRK opened at $106.38 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $269.44 billion, a P/E ratio of 118.20, a P/E/G ratio of 1.55 and a beta of 0.39. Merck & Co., Inc. has a 52-week low of $99.80 and a 52-week high of $134.63. The firm has a 50-day moving average price of $113.86 and a 200 day moving average price of $121.93.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. UBS Group lowered their price objective on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Truist Financial cut their price objective on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Sanford C. Bernstein started coverage on shares of Merck & Co., Inc. in a research report on Thursday, October 17th. They issued a “market perform” rating and a $115.00 target price on the stock. Morgan Stanley lifted their price target on shares of Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday, July 11th. Finally, Evercore ISI upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $131.62.
Get Our Latest Analysis on Merck & Co., Inc.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- How to Use the MarketBeat Stock Screener
- CrowdStrike Sees Unusual Call Option Surge: What’s Next?
- Comparing and Trading High PE Ratio Stocks
- GM Stock Is Crushing the Competition in 2024 – Is It Time to Buy?
- How to Invest in the FAANG Stocks
- The Nuclear Shift: 3 Best Uranium ETFs to Invest in for 2024
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.